title: A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences.
abstract: BACKGROUND
  A cost-effectiveness model that accurately represents disease progression, outcomes, and associated costs is necessary to evaluate the cost-effectiveness of interventions for chronic kidney disease (CKD).
  
  
  METHODS
  We developed a microsimulation model of the incidence, progression, and treatment of CKD. The model was validated by comparing its predictions with survey and epidemiologic data sources.
  
  
  METHODS
  US patients.
  
  
  METHODS
  The model follows up disease progression in a cohort of simulated patients aged 30 until age 90 years or death. The model consists of 7 mutually exclusive states representing no CKD, 5 stages of CKD, and death. Progression through the stages is governed by a person's glomerular filtration rate and albuminuria status. Diabetes, hypertension, and other risk factors influence CKD and the development of CKD complications in the model. Costs are evaluated from the health care system perspective.
  
  
  METHODS
  Usual care, including incidental screening for persons with diabetes or hypertension.
  
  
  RESULTS
  Progression to CKD stages, complications, and mortality.
  
  
  RESULTS
  The model provides reasonably accurate estimates of CKD prevalence by stage. The model predicts that 47.1% of 30-year-olds will develop CKD during their lifetime, with 1.7%, 6.9%, 27.3%, 6.9%, and 4.4% ending at stages 1-5, respectively. Approximately 11% of persons who reach stage 3 will eventually progress to stage 5. The model also predicts that 3.7% of persons will develop end-stage renal disease compared with an estimate of 3.0% based on current end-stage renal disease lifetime incidence.
  
  
  CONCLUSIONS
  The model synthesizes data from multiple sources rather than a single source and relies on explicit assumptions about progression. The model does not include acute kidney failure.
  
  
  CONCLUSIONS
  The model is well validated and can be used to evaluate the cost-effectiveness of CKD interventions. The model also can be updated as better data for CKD progression become available.
authors.affiliation: RTI International, Research Triangle Park, NC 27709, USA. tjh@rti.org
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Hoerger
authors.forename: John S
authors.initials: JS
authors.lastname: Wittenborn
authors.forename: Joel E
authors.initials: JE
authors.lastname: Segel
authors.forename: Nilka R
authors.initials: NR
authors.lastname: Burrows
authors.forename: Kumiko
authors.initials: K
authors.lastname: Imai
authors.forename: Paul
authors.initials: P
authors.lastname: Eggers
authors.forename: Meda E
authors.initials: ME
authors.lastname: Pavkov
authors.forename: Regina
authors.initials: R
authors.lastname: Jordan
authors.forename: Susan M
authors.initials: SM
authors.lastname: Hailpern
authors.forename: Anton C
authors.initials: AC
authors.lastname: Schoolwerth
authors.forename: Desmond E
authors.initials: DE
authors.lastname: Williams
mesh_terms: D000328:Adult; D000419:Albuminuria / Q000175:diagnosis / Q000209:etiology; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D005260:Female; D006291:Health Policy; D006801:Humans; D015994:Incidence; D007674:Kidney Diseases / Q000150:complications / Q000175:diagnosis* / Q000191:economics*; D008297:Male; D008962:Models, Theoretical